Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients

Servier

Status and phase: Terminated; Phase 2

Conditions: Mild Cognitive Impairment

Treatments: Drug: S18986

Study type: Interventional

Funder types: Other

Identifiers

NCT00202540

CL2-18986-009

Details and patient eligibility

About

The purpose of this study is to demonstrate a long term efficacy of S18986 versus placebo on episodic memory performance in patients with MCI

Enrollment: 38 patients

Sex: All

Ages: 55+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Memory complaint
• Acetylcholinesterase inhibitors stopped at least 3 months before selection

Exclusion criteria

• Dementia
• Parkinson's disease
• Vascular disorder
• Depression
• Epilepsy